News
ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio
19 Apr 24
News
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
14 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5
14 Mar 24
News, Price Target, Analyst Ratings
ProQR Therapeutics FY EPS $(0.38) Up From $(0.97) YoY
13 Mar 24
Earnings, News
Press releases
ProQR Achieves Successful Defense of New Challenge to its Axiomerâ„¢ IP Portfolio
19 Apr 24
Press Releases
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 24
Biotech, Press Releases, General
ProQR Announces Japanese Axiomerâ„¢ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
15 Feb 24
Biotech, Press Releases, General